Ask AI
ProCE Banner Activity

Expert Guidance for the Selection of Systemic Agents in Myelofibrosis

Tool

The expanding range of JAK inhibitor options in myelofibrosis has increased the need for individualized treatment decisions that account for disease characteristics, molecular findings, prior therapy, comorbidities, cytopenias, symptoms, and patient-specific goals. This Interactive Decision Support Tool applies key patient and disease characteristics to treatment selections and compares their intended approach with recommendations from MF experts, exploring how clinical evidence, supportive care needs, and patient factors can inform personalized, equitable management across diverse patient populations.

Released: October 30, 2026

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education In partnership with Smart Patients, Inc.

ProCE Banner

Supporters

This educational activity is supported by independent medical education grants from GSK, Incyte Corporation, and Sobi.

GSK

Incyte Corporation

Sobi

Partners

Smart Patients, Inc.

ProCE Banner

Target Audience

This activity is intended for oncologists, hematologists, nurses, pharmacists, and other healthcare professionals who care for patients with myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Plan individualized treatment strategies for patients with MF, considering patient medical and treatment history, available clinical evidence, and expert guidelines

Financial Disclosures

Primary Author

John Mascarenhas, MD: researcher: Ajax, Bristol Myers Squibb, Disc, Geron, Incyte, Italfarmaco, Kartos, Karyopharm, Novartis, PharmaEssentia, Sobi; consultant/advisor/speaker: Bristol Myers Squibb, Cogent, Damora, Disc, Galecto, Geron, Incyte, Italfarmaco, Karyopharm, Merck, Novartis, PharmaEssentia, Roche, Sobi, Sumitomo.

Kristen Pettit, MD: consultant/advisor/speaker: PharmaEssentia, Protagonist; researcher (paid to institution): AbbVie, Ajax, GSK, Incyte, Janssen, Kartos, Merck, Protagonist.

Raajit K. Rampal, MD, PhD: consultant/advisor/speaker: AbbVie, Blueprint, Bristol Myers Squibb, Cogent, Constellation/Morphosys, CTI BioPharma/Sobi, Dainippon, Disc Medicine, Galecto, Incyte, Jazz, Kartos, Karyopharm, Novartis, OPNA, PharmaEssentia, Promedior, Sierra Oncology/GSK, Stemline, Sumitomo, Zentalis; researcher: Biomed Valley Discoveries, Constellation/Morphosys, Incyte, Ryvu, Stemline, Zentalis.

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose. 

Abdulraheem Yacoub, MD, has no relevant relationships to disclose.

Additional Disclosures

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.